Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 75
Filtrar
1.
J Eur Acad Dermatol Venereol ; 30(10): 1657-1669, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27406069

RESUMO

BACKGROUND: The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical guidelines on its use in dermatological conditions were established in 2008 and renewed in 2011. MATERIALS AND METHODS: The European guidelines presented here were prepared by a panel of experts nominated by the EDF and the EADV. The guidelines were developed to update the indications for treatment currently considered as effective and to summarize the evidence base for the use of IVIg in dermatological autoimmune diseases and TEN. RESULTS AND CONCLUSION: The current guidelines represent consensual expert opinions and definitions on the use of IVIg reflecting current published evidence and are intended to serve as a decision-making tool for the use of IVIg in dermatological diseases.


Assuntos
Doenças Autoimunes/terapia , Imunoglobulinas Intravenosas/administração & dosagem , Dermatopatias/terapia , Europa (Continente) , Humanos , Imunoglobulinas Intravenosas/uso terapêutico
3.
Br J Dermatol ; 171(4): 891-4, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24725144

RESUMO

BACKGROUND: Primary cutaneous γ/δ T-cell lymphoma (PCGD-TCL) is aggressive and has a poor prognosis. In contrast, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) of the α/ß T-cell receptor phenotype is known to follow an indolent course and have a more favourable prognosis. In the past, PCGD-TCL and SPTCL were often considered to be a manifestation of the same disease, and aggressive systemic polychemotherapy has commonly been the first-line therapy for both. Given the understanding that SPTCL is a separate and less aggressive entity, clinical data exclusively evaluating the efficacy of conservative treatment in SPTCL are needed. OBJECTIVES: To assess the overall clinical response to systemic corticosteroids in the treatment of SPTCL. METHODS: This was a retrospective cross-sectional study based on a patient data repository from two tertiary care university hospitals in Zürich (Switzerland) and Tübingen (Germany). The repository spanned 13 years. RESULTS: In four of the five patients (80%) with SPTCL, treatment with systemic corticosteroids induced a complete remission. CONCLUSIONS: Systemic corticosteroids may be an excellent first-line single-agent therapy for SPTCL.


Assuntos
Antineoplásicos Hormonais/uso terapêutico , Linfoma de Células T/tratamento farmacológico , Paniculite/tratamento farmacológico , Prednisolona/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Adulto , Idoso , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
4.
Andrologia ; 46(7): 731-7, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23879209

RESUMO

We conducted a longitudinal cohort study on the quality of life of infertile male patients measured at baseline and after 5 years with a specific quality of life instrument for male patients who are involuntarily childless. It was distributed to patients who were seen at the andrology and gynaecology clinics for infertility diagnoses and treatment. At baseline (T1), 275 patients took part in the study. A subset of these patients (N = 133) had released two semen samples, and the results of the semen analysis had been communicated to them before they received the questionnaire. Semen quality of this subset was assessed according to WHO recommendations. After 5 years (T2), the questionnaires were mailed again and were sent back by N = 101 patients. No significant quality of life difference was found between the semen quality groups. After 5 years, an improvement was found for the dimensions 'desire for a child' [mean score 1.92 (T1) versus 1.72 (T2)] and 'gender identity' [mean score 1.56 (T1) versus 1.42 (T2)] while no change was found for 'partnership' and 'psychological well-being'. We did not find significant differences between patients who had fathered a child in the meantime and patients who did not become fathers.


Assuntos
Infertilidade Masculina/fisiopatologia , Estudos Longitudinais , Qualidade de Vida , Adulto , Seguimentos , Humanos , Masculino , Inquéritos e Questionários
5.
Z Rheumatol ; 71(8): 685-96; quiz 697, 2012 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-23052559

RESUMO

Behçet's disease is a systemic disorder with the histopathological correlate of leukocytoclastic vasculitis. Pathogenetically, besides a strong genetic component participation of the innate immune system and an autoinflammatory component are discussed. The disease is most common in countries along the former silk route but in Germany the disease is rare (prevalence approximately 0.6/100,000). Oral aphthous ulcers are the main symptom, followed by skin manifestations, genital ulcers and oligoarthritis of large joints. Severe manifestations, threatening quality of life and even life itself, are the gastrointestinal manifestations which often perforate, arterial, mainly pulmonary arterial aneurysms which cause life-threatening bleeding, CNS manifestations and ocular disease, which with occlusive retinal vasculitis often leads to blindness. For milder manifestations low-dose steroids and colchicine are used, for moderate manifestations such as arthritis or ocular disease not immediately threatening visual acuity, azathioprin or cyclosporin A are combined with steroids. For severe manifestations, interferon-alpha, TNF-antagonists or cytotoxic drugs are recommended. Interleukin 1 (IL-1) antagonists are currently being examined in clinical studies.


Assuntos
Síndrome de Behçet/tratamento farmacológico , Síndrome de Behçet/terapia , Ciclosporina/uso terapêutico , Imunossupressores/uso terapêutico , Esteroides/uso terapêutico , Humanos
6.
Ophthalmologe ; 109(6): 548-57, 2012 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-22699945

RESUMO

Behcet's disease is a multisystem disorder with the histopathological correlate of leukocytoclastic vasculitis. The classification criteria for the disease include the presence of recurrent oral aphthous ulcers combined with at least two other manifestations, such as genital aphthous ulcers, skin manifestations (mostly erythema nodosa or pseudofolliculitis) and ocular manifestations (panuveitis or posterior uveitis with retinal vasculitis). A positive pathergy test is regarded as pathognomonic for the disease and a sterile papulopustule occurs after a sterile needle prick of the forearm. However, this test is positive in only 15% of the patients. The prognosis of Behcet's disease becomes unfavorable when vital organs are involved. This is the case for involvement of the central nervous system which occurs in 10% of patients, arterial and pulmonary arterial aneurysms and gastrointestinal involvement, which clinically and histopathologically is difficult to differentiate from inflammatory bowel disease but tends to perforate. Oligoarthritis, which occurs in approximately 50% of the patients, causes problems concerning the differential diagnosis from classical forms of spondyloarthritis. Behcet's disease is associated with HLA-B51 in 50-80% of the cases depending on the country of origin of the patient. The prognosis becomes unfavorable if the disease manifests in young male patients. The treatment of extraocular manifestations depends on the aggressiveness. Milder manifestations are treated with low dose prednisolone and steroid sparing immunosuppressants, such as azathioprine or cyclosporine A. In cases with more severe manifestations, such as central nervous system (CNS) involvement cyclophosphamide or TNF antagonists and in selected cases also interferon alpha can be considered.


Assuntos
Artrite/diagnóstico , Artrite/terapia , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/terapia , Vasculite Leucocitoclástica Cutânea/diagnóstico , Vasculite Leucocitoclástica Cutânea/terapia , Humanos , Masculino
8.
Eur J Radiol ; 74(3): e38-44, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19467811

RESUMO

Metastases from uveal melanoma are often confined to the liver. Palliative hepatic chemoembolization has been considered to be a reasonable treatment approach. We enrolled 14 patients with hepatic metastases from uveal melanoma into a pilot trial of transarterial chemoembolization (TACE). All patients received additional systemic immuno-chemotherapy or best supportive care. In 31 procedures 100mg/m(2) of cisplatine was continuously infused by means of a power injector preceding embolization by manual injection of polyvinyl alcohol particles. In three procedures cisplatine was replaced by 200mg/m(2) carboplatine because of increased serum creatinine levels. Tumor response was evaluated using RECIST criteria. Fourteen patients received 34 TACE's (mean: 2.4 treatments). Eight patients (57%) achieved partial response (PR), four patients (29%) had stable disease and two patients (14%) tumor progression. Median time to progression was 8.5 months (5-35 months). Median survival after first TACE was 14.5 months in responders compared to 10 months in non-responders (p=0.18, not significant) and 11.5 months (3-69 months) in all patients. In seven patients with metastases occupying less than 25% of liver volume median survival was 17 months compared to 11 months in seven patients with tumor involvement of more than 25% (p=0.02) with partial response rate of 86% and 29%, respectively. TACE of liver metastases from uveal melanoma is well tolerated and may prolong survival in patients with limited tumor extension.


Assuntos
Embolização Terapêutica/métodos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/secundário , Melanoma/tratamento farmacológico , Melanoma/secundário , Álcool de Polivinil/uso terapêutico , Neoplasias Uveais/tratamento farmacológico , Feminino , Hemostáticos/uso terapêutico , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Masculino , Melanoma/diagnóstico , Projetos Piloto , Resultado do Tratamento , Neoplasias Uveais/diagnóstico
9.
Hautarzt ; 60(6): 477-82, 2009 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-19387594

RESUMO

Affects on male fertility are associated with many sexually transmitted diseases. Genital tract infections play a major role in this context. The evidence for an impact on fertility differs for the pathogens; however early treatment may be very important. This requires fast and precise clinical diagnostics. Further, sexually transmitted infections may have major relevance in andrologic diagnostics because of the risk of transmission to the mother or fetus. Particularly for the increasingly relevant HIV and hepatitis infections, current guidelines are available for use in diagnostics and assisted reproduction techniques.


Assuntos
Andrologia/tendências , Infertilidade Masculina/diagnóstico , Infertilidade Masculina/prevenção & controle , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/terapia , Humanos , Infertilidade Masculina/etiologia , Masculino , Infecções Sexualmente Transmissíveis/complicações
11.
Skeletal Radiol ; 37(10): 885-94, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18622607

RESUMO

OBJECTIVE: To describe musculocutaneous MR-findings responsible for disability in chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT). MATERIAL AND METHODS: Between June 2005 and February 2008, we performed whole-body musculoskeletal magnetic resonance imaging (MRI; n = 12) or regional MRI (n = 4) in 16 consecutive patients presenting with disabling sclerodermatous cGVHD (e.g., skin edema, fixed deep dermal sclerosis, joint contractures, painful muscular contractures, or myalgia). RESULTS: In all patients, MRI showed musculocutaneous abnormalities reflecting different degrees of inflammation and collagen tissue involvement of the skin (n = 10), subcutaneous fat tissue (n = 13), muscle fasciae (n = 16), subfascial muscular septae (n = 6), or findings compatible with myositis (n = 3). The most frequently involved muscle fasciae comprised those of the vastus lateralis muscle (n = 12), biceps femoris muscle (n = 11), gastrocnemius medialis muscle (n = 8), serratus anterior muscle, and latissimus dorsi muscle (each, n = 5). Increased signal of involved tissues on STIR-images and fat-saturated postgadolinium T1-weighted images represented the most frequent MR-signal abnormalities. CONCLUSION: MR imaging of musculocutaneous cGVHD allows accurate evaluation including assessment of deep tissue infiltration and assists in the differential diagnosis.


Assuntos
Doença Enxerto-Hospedeiro/diagnóstico , Imageamento por Ressonância Magnética/métodos , Doenças Musculares/diagnóstico , Dermatopatias/diagnóstico , Imagem Corporal Total , Adulto , Idoso , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
12.
Rheumatology (Oxford) ; 47(8): 1185-92, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18515867

RESUMO

OBJECTIVE: Systemic sclerosis (SSc) is a rare, heterogeneous disease, which affects different organs and therefore requires interdisciplinary diagnostic and therapeutic management. To improve the detection and follow-up of patients presenting with different disease manifestations, an interdisciplinary registry was founded with contributions from different subspecialties involved in the care of patients with SSc. METHODS: A questionnaire was developed to collect a core set of clinical data to determine the current disease status. Patients were grouped into five descriptive disease subsets, i.e. lcSSc, dcSSc, SSc sine scleroderma, overlap-syndrome and UCTD with scleroderma features. RESULTS: Of the 1483 patients, 45.5% of patients had lcSSc and 32.7% dcSSc. Overlap syndrome was diagnosed in 10.9% of patients, while 8.8% had an undifferentiated form. SSc sine scleroderma was present in 1.5% of patients. Organ involvement was markedly different between subsets; pulmonary fibrosis for instance was significantly more frequent in dcSSc (56.1%) than in overlap syndrome (30.6%) or lcSSc (20.8%). Pulmonary hypertension was more common in dcSSc (18.5%) compared with lcSSc (14.9%), overlap syndrome (8.2%) and undifferentiated disease (4.1%). Musculoskeletal involvement was typical for overlap syndromes (67.6%). A family history of rheumatic disease was reported in 17.2% of patients and was associated with early disease onset (P < 0.005). CONCLUSION: In this nationwide register, a descriptive classification of patients with disease manifestations characteristic of SSc in five groups allows to include a broader spectrum of patients with features of SSc.


Assuntos
Escleroderma Sistêmico/epidemiologia , Adulto , Distribuição por Idade , Idade de Início , Idoso , Estudos Transversais , Feminino , Alemanha/epidemiologia , Humanos , Masculino , Medicina , Pessoa de Meia-Idade , Sistema de Registros , Esclerodermia Difusa/epidemiologia , Esclerodermia Difusa/patologia , Esclerodermia Limitada/epidemiologia , Esclerodermia Limitada/patologia , Escleroderma Sistêmico/classificação , Escleroderma Sistêmico/patologia , Especialização
16.
Hum Reprod ; 20(10): 2858-65, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15980002

RESUMO

BACKGROUND: Infertility may considerably reduce quality-of-life. Many of the existing generic quality-of-life measures, which often focus on physical impairments, do not represent the specific complaints of infertile patients. In this article, we report on the development and validation of the TLMK (Tübinger Lebensqualitätsfragebogen für Männer mit Kinderwunsch), an instrument for measuring quality-of-life in male patients with involuntary childlessness. METHODS: The first version of the questionnaire, which consisted of 91 items, was administered to 275 men who attended andrology and gynaecology clinics for fertility evaluations. After the questionnaires were scored, item analysis and reduction, principal component analysis and internal consistency analyses were conducted. RESULTS: The final version of the TLMK consists of 35 items in four scales and provides an internally consistent quality-of-life profile for men experiencing involuntary childlessness. Convergent and discriminant validity was supported through the correlation of the TLMK scales with established questionnaires on life satisfaction (FLZ) and partnership (PFB). CONCLUSION: The TLMK provides information about the quality-of-life in men experiencing involuntary childlessness and was found to be easy to administer and acceptable to patients. It may be used to assess patients' baseline and ongoing quality-of-life during fertility treatment and as an outcome variable in the evaluation of integrated psychological counselling.


Assuntos
Infertilidade Masculina/psicologia , Psicometria/métodos , Adulto , Idoso , Atitude , Indicadores Básicos de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Análise de Componente Principal , Qualidade de Vida , Reprodutibilidade dos Testes , Medicina Reprodutiva/métodos , Projetos de Pesquisa , Classe Social , Inquéritos e Questionários
19.
Melanoma Res ; 12(4): 395-8, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12170190

RESUMO

Anorectal malignant melanoma is an uncommon tumour. Unlike for cutaneous melanoma, there are few guidelines for its optimal management. In particular, very few palliative treatment strategies have been described for patients with advanced disease. We report on an 80 year old patient with locally advanced anorectal melanoma nearly completely blocking the anal orifice and disseminated metastases. Complete regression of the primary tumour and partial remission of the metastases was achieved with intratumoral injections of natural interferon-beta and systemic administration of dacarbazine. The quality of life in this patient was improved markedly by providing relief from severe rectal pain and bleeding. We propose that conservative treatment strategies such as intratumoral injections with interferon-beta should be considered as a palliative treatment option for stenosing anorectal melanoma before an abdominoperineal resection is recommended.


Assuntos
Neoplasias do Ânus/tratamento farmacológico , Fatores Imunológicos/uso terapêutico , Interferon beta/uso terapêutico , Melanoma/tratamento farmacológico , Cuidados Paliativos , Neoplasias Retais/tratamento farmacológico , Idoso , Antineoplásicos Alquilantes/uso terapêutico , Neoplasias do Ânus/complicações , Neoplasias do Ânus/patologia , Terapia Combinada , Constrição Patológica , Dacarbazina/uso terapêutico , Feminino , Hemorragia Gastrointestinal/etiologia , Humanos , Fatores Imunológicos/administração & dosagem , Injeções Intralesionais , Interferon beta/administração & dosagem , Neoplasias Pulmonares/secundário , Metástase Linfática , Melanoma/complicações , Melanoma/patologia , Melanoma/secundário , Qualidade de Vida , Neoplasias Retais/patologia , Prolapso Retal/etiologia , Indução de Remissão
20.
Br J Dermatol ; 147(1): 174-8, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12100205

RESUMO

Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been shown to be effective in transplant patients. Some case reports and pilot studies have suggested efficacy against systemic lupus erythematosus (LE), particularly in the case of lupus nephritis. Reports on MMF treatment of skin manifestations of LE are still anecdotal. We report two cases with extensive skin lesions owing to subacute cutaneous LE (SCLE). Both patients had been treated with azathioprine and antimalarials without effect. Finally both patients were given highly dosed glucocorticosteroids, which were also ineffective but led to vertebral fractures because of long-term steroid treatment in one patient and steroid-induced psychosis in the other. MMF 2 g daily caused the skin manifestations to disappear within a few weeks in both patients. One patient was followed up for more than 24 months, and showed good toleration of MMF treatment. The skin remained stable over this period when at least 1 g MMF per day was administered. In conclusion, MMF appears to be an attractive treatment option in skin manifestations of SCLE, and seems to be beneficial for patients with steroid-refractory lesions that are also resistant to treatment with immunosuppressants or antimalarials. The observations suggest that further evaluation of this route in randomized controlled trials is warranted.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Imunossupressores/uso terapêutico , Lúpus Eritematoso Cutâneo/tratamento farmacológico , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...